Dr. Guru Sonpavde, MD (Clinical Assistant Professor, Baylor College of Medicine) reported about an open label, phase II trial of sunitinib (Sunitinib, marketed as Sutent, and previously known as SU11248 is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and [...]
Advanced prostate cancer will progress and most of us will face a time when Androgen Deprivation Therapy (ADT) stops working. Most men on ADT take a LHRH agonist, which turns off the production of testosterone (i.e. Lupron) along with a non-steroidal anti-androgen (i.e. Casodex) that prevents the small amount of testosterone that continues to be [...]
The use of Docetaxel (chemotherapy) extends survival time in men with castration-resistant prostate cancer (CRPC). Many researchers believe that platinum compounds, particularly Carboplatin, when added to docetaxel (taxane-based chemotherapy) can further extend survival times. A study at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Investigated the efficacy [...]
Docetaxel (Taxotere), or chemotherapy, will as all other treatments for advanced prostate cancer stop working. Many of us will progress quickly to this stage and eventually face a situation where there are no longer any approved treatments available to control our prostate cancer. If you are lucky enough to have an oncologist who is creative [...]
Cancer Care is conducting a telephone workshop on Metastatic Prostate Cancer on Tuesday, September 22, 2009 from 1:30 to 2:30 eastern time. Listening in on the workshop is free. Participants in the workshop will be: Susan Slovin MD, PhD, Associate Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for the Treatment of Prostate & Urologic [...]